Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is ...

The FDA has followed the advice of its expert advisors and rejected Cytokinetics’ cardiac myosin activator omecamtiv mecarbil as a treatment for heart failure, saying the efficacy data for the ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

A biotech in­cu­bat­ed by RA Cap­i­tal has se­cured a $57.5 mil­lion Se­ries B to be­gin a mid-stage tri­al for its car­dio drug this quar­ter and … ...

At close: 11 April at 16:00:01 GMT-4 ...

At close: April 11 at 4:00:01 PM EDT ...